more frequent among younger patients. 9 Importantly, rates of stroke, AMI, ESRD, and amputations showed a smaller reduction in the population without DM, suggesting that greater progress had been accomplished in the treatment of diabetic patients. 9 The authors attributed their findings to improved (1) preventative health care, (2) treatment of acute complications, (3) availability of drugs and therapeutic procedures (eg, revascularization), and (4) earlier detection and management of diabetic complications. 9 Even neuropathy, which remains a frequently overlooked complication, 10 can now be diagnosed more reliably by new tests. 11 Moreover, there appears to have been some improvement in lifestyle factors such as smoking and dietary habits as well as in self-monitoring of blood glucose. 9 These achievements notwithstanding, the overall burden of diabetic complications has not been reduced, 9 at least not to the extent that was set as a goal by the St Vincent declaration. 12, 13 This is primarily attributable to the growing diabetes epidemic, which is, in turn, due to urbanization, Westernized dietary habits, obesity, and prolonged life expectancy. 9, 14 Arguably, obesity and industrialization apply more to patients with T2DM, while prolonged survival after diagnosis, resulting in increased lifetime DM duration, applies more not only to patients with T1DM but also to patients with T2DM.
The New England Journal of Medicine analysis has its limitations. 9 These include the lack of data on microvascular diabetic complications and hypoglycemia, the failure to compare complication rates between the 2 DM types as well as the absence of more detailed ascertainment of the progress hitherto achieved in DM management and adherence to guidelines. Accordingly, further data are now desirable in an endeavor to increase our knowledge in these areas.
In this context, some improvements are now highly welcome. First, it would be useful to obtain more data on less well-studied factors, notably advanced glycated end products (AGEs). 15 These molecules are being increasingly linked to chronic inflammation and oxidative stress, which contribute to the development of DM and its complications. 15 Hence, it is worth considering strategies to identify patients with high AGEs and explore how these may be reduced with treatment and/or healthy diet. 15 Second, emerging cardiovascular markers, like serum uric acid 16, 17 and bilirubin, 18 as well as new therapeutic priorities, such as nonalcoholic fatty liver disease (NAFLD), 19 deserve attention. In the light of current knowledge, metabolic disorders including obesity, metabolic syndrome, and NAFLD should be prevented or at least diagnosed earlier and treated in order to prevent or delay the onset of T2DM. The effects of other commonly prescribed drugs, such as statins and antihypertensive agents, on glucose metabolism should also be taken into consideration. Indeed, statin therapy has been related to new-onset DM in a dose-dependent manner. 20 Of note, reninangiotensin system (RAS) inhibitors may exert a beneficial effect on metabolic parameters and diabetic complications, thus representing the first-drug choice in patients with DM. Interestingly, combination of a statin and RAS inhibitors has been shown to further decrease vascular morbidity and mortality in diabetic patients compared with either monotherapy. 21 Third, there is a need for new oral hypoglycemic agents with fewer untoward effects like hypoglycemia and weight gain. Some of these are the sodium glucose cotransport inhibitors 22, 23 and interleukin 1b inhibitors. 24, 25 Finally, new, easier-to-use insulin pens that are now being launched may turn out to improve patient adherence. 26 Despite a substantial decline in the rates of 5 major DM complications in the United States during the past 2 decades, further progress is required due to the consistent increase in DM prevalence. 9 It is true that a complete picture could not be obtained due to the absence of some information. 9 However, the new data are very useful because the scientific community has previously been disappointed by lack of standardized criteria and classification methods, 27 inconsistent reporting of research findings, 28 and lack of agreement on choice of end points even in landmark trials, leading to their erratic interpretation. 29 In conclusion, the New England Journal of Medicine publication has demonstrated encouraging improvements in terms of 5 major DM complications (AMI, stroke, ESRD, death from hyperglycemic crisis, and amputations) between 1990 and 2010 in the United States. 9 However, this progress may not prove enough in the face of the DM epidemic. 9, 13, 17 For the medical world, the ultimate challenge is how we can learn from past mistakes and successfully seek new solutions to improve the prevention and treatment of DM and its complications.
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